Table 2.
Amino acid substitutions, antifungal agent MICs, and patient’s characteristics for 22 Candida tropicalis clinical isolates
| Designation | Origin | Date of isolation | Age /Sex | Underlying disease | Ward | Substitution of amino acid residue (Erg11p) | DST | Antifungal agent MIC (mg/L) | Previous azole usea | Antifungal therapy | Thirty-day outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FLU | VOR | ITR | POS | AMB | 5FC | |||||||||||
| Ct01R | Blood | 8/5/15 | 37/M | ALL | Hematology | Y132F, S154F | 225 | 128 | 4 | 0.25 | 0.25 | 0.5 | ≤0.06 | FLU, VOR | CAS, AMB | Survival |
| Ct02R | Pleural fluid | 10/4/14 | 65/M | Liver Transplantation | ICU | None | 639 | 8 | 0.5 | 0.25 | 0.25 | 0.5 | ≤0.06 | VOR | None | Death |
| Ct03R | Blood | 9/12/13 | 72/F | Chronic Renal Failure | Gastroenterological Surgery | Y132F, S154F | 639 | 256 | 4 | 0.5 | 0.5 | 0.5 | 0.25 | None | FLU, AMB | Death |
| Ct04R | Blood | 11/8/13 | 26/M | ALL | Hematology | Y132F, S154F | 329 | 64 | 2 | 0.25 | 0.25 | 0.5 | ≤0.06 | FLU | ITR | Survival |
| Ct05R | Blood | 2/22/15 | 40/M | CML | Hematology | Y132F, S154F | 615 | 128 | 4 | 0.25 | 0.5 | 0.5 | 0.12 | FLU, ITR | CAS | Survival |
| Ct06R | Blood | 4/6/17 | 38/M | AML | Hematology | Y132F, S154F | NT | 128 | 4 | 0.5 | 0.5 | 0.5 | 0.12 | FLU, VOR | CAS, AMB | Survival |
| Ct07R | Urine | 9/15/14 | 87/F | Cholangitis | ICU | Y132F, S154F | 225 | 256 | > 8 | 1 | 1 | 0.5 | ≤0.06 | None | None | Survival |
| Ct08R | Urine | 7/22/15 | 19/M | Nephrlithotomy | Urology | Y132F, S154F | 225 | 64 | 4 | 0.5 | 1 | 1 | ≤0.06 | None | VOR | Survival |
| Ct09R | Urine | 8/7/15 | 64/M | Pneumonia | Respiratory | Y132F, S154F | 225 | > 256 | 8 | 1 | 1 | 1 | ≤0.06 | None | None | Survival |
| Ct10R | Blood | 9/2/15 | 25/F | ALL | Hematology | Y132F, S154F | 506 | > 256 | 8 | 1 | 1 | 1 | ≤0.06 | ITR | CAS | Survival |
| Ct11R | Urine | 9/26/15 | 80/M | Pneumonia | ICU | Y132F, S154F | 508 | 64 | 2 | 0.25 | 0.25 | 0.5 | ≤0.06 | None | None | Death |
| Ct12R | Urine | 6/17/15 | 83/F | Adrenocortical Carcinoma | ICU | Y132F, S154F | 508 | 64 | 4 | 0.25 | 0.25 | 0.5 | ≤0.06 | None | None | Death |
| Ct01S | Cervix | 4/5/17 | 34/F | Premature Delivery | Obstetrics | None | NT | 2 | 0.12 | 0.12 | 0.12 | 0.25 | ≤0.06 | None | None | Survival |
| Ct02S | Sputum | 6/15/17 | 62/M | Respiratory Failure | Respiratory | None | NT | 1 | 0.12 | 0.12 | 0.12 | 0.25 | ≤0.06 | None | None | Survival |
| Ct03S | Urine | 6/23/17 | 16/F | Ewing’s Sarcoma | Musculoskeletal Tumor | None | NT | 1 | 0.06 | 0.12 | 0.12 | 0.25 | 0.12 | None | FLU | Survival |
| Ct04S | Catheter | 6/26/17 | 44/M | Hepatocellular Carcinoma | ICU | None | NT | 2 | 0.12 | 0.25 | 0.25 | 0.25 | ≤0.06 | None | None | Death |
| Ct05S | Blood | 11/27/14 | 50/M | Cirrhosis | Hepatology | None | 519 | 2 | 0.12 | 0.25 | 0.25 | 1 | ≤0.06 | None | CAS | Survival |
| Ct06S | Blood | 2/13/15 | 43/M | AML | Hematology | None | 169 | 1 | 0.12 | 0.25 | 0.5 | 0.5 | ≤0.06 | None | ITR | Death |
| Ct07S | Urine | 7/3/15 | 80/M | CHD | Cardiology | None | 343 | 1 | 0.12 | 0.25 | 0.25 | 0.5 | 0.25 | None | None | Survival |
| Ct08S | Blood | 9/25/15 | 42/M | AML | Hematology | None | 399 | 1 | 0.12 | 0.25 | 0.12 | 1 | 0.12 | None | VOR, AMB | Death |
| Ct09S | Blood | 10/31/14 | 51/F | AML | Hematology | None | 300 | 2 | 0.25 | 0.25 | 0.25 | 0.5 | 0.12 | None | VOR, AMB | Death |
| Ct10S | Urine | 7/26/17 | 23/M | HPS | ICU | None | 169 | 1 | 0.12 | 0.25 | 0.25 | 0.5 | ≤0.06 | None | None | Survival |
5FC 5-flucytosine, ALL acute lymphocytic leukemia, AMB amphotericin B, AML acute myeloid leukemia, CAS caspofungin, CHD coronary heart disease, CML chronic myeloid leukemia, FLU fluconazole, HPS hemophagocytic syndrome, ITR itraconazole, NT untyped, POS posaconazole, VOR voriconazole
awithin 3 months prior to the detection of C. tropicalis